Mektovi

Binimetinib, the active ingredient in Mektovi, is a MEK inhibitor presented as a tablet for oral use. It is indicated for the treatment of BRAF V600 mutation‑positive unresectable or metastatic melanoma in adult patients.

GNH USA supplies Mektovi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product for global distribution.

Mektovi (binimetinib) is used in the management of cancers driven by the MAPK/ERK pathway, particularly melanoma with a BRAF V600 mutation.

- BRAF V600 mutation‑positive unresectable or metastatic melanoma: reduces tumor growth and prolongs progression‑free survival.

Mektovi may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling of sickness. - Vomiting: expulsion of stomach contents. - Rash: skin irritation or redness. - Fatigue: persistent tiredness. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - Interstitial lung disease: inflammation of lung tissue. - Retinal disorders: visual disturbances or vision loss. - Elevated liver enzymes: potential hepatic injury. - Cardiac dysfunction: reduced ejection fraction or heart failure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemorrhage: increased risk of bleeding.

Before initiating therapy with Mektovi, several safety considerations should be addressed. - Dose adjustment: required in patients with hepatic impairment. - Cardiac monitoring: assess left ventricular ejection fraction prior to and during treatment. - Ophthalmologic evaluation: baseline eye exam and periodic monitoring for retinal toxicity. - Pregnancy and lactation: avoid use due to unknown fetal risk. - Drug interactions: review concomitant medications for potential CYP3A4 effects. - Store at ambient temperature below 25 °C: keep in the original pack, protect from moisture.

Mektovi can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce binimetinib exposure. - Concurrent use with other MEK inhibitors: increases risk of overlapping toxicities. - QT‑prolonging agents: heightens potential for cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - Immunosuppressants (e.g., tacrolimus): potential alteration of therapeutic effect. - Oral contraceptives: reduced hormonal efficacy, consider alternative contraception.